Aaps Pharmscitech

AAPS PharmSciTech is the online-only journal of the American Association of Pharmaceutical Scientists, published by Springer and founded in 2000, covering the design, development and evaluation of dosage forms and delivery systems and the manufacturing science behind their commercialisation, with a 2025 Journal Impact Factor of 5.1.《AAPS 制药技术》是美国药物科学家协会的纯在线期刊，由（Springer）出版，2000 年创刊，涵盖剂型与给药系统的设计、开发与评价，以及其商业化背后的制造科学，2025 年期刊影响因子为 5.1。

Scope

• Research, development and evaluation of pharmaceutical dosage forms, from preformulation through formulation design to the finished product.药物剂型的研究、开发与评价，从预处方、处方设计一直到成品。
• Drugs derived from biotechnology, including peptides, proteins, antibodies, nucleic acids and cell-based products.生物技术来源的药物，包括多肽、蛋白、抗体、核酸与细胞类产品。
• Delivery systems such as nanoparticles, liposomes, microneedles, implants, in situ gels, long-acting depots and pulmonary or nasal platforms.纳米粒、脂质体、微针、植入剂、原位凝胶、长效储库以及肺部与鼻腔给药平台等递送系统。
• Manufacturing science for commercialisation, including process design, scale-up, process analytical technology, quality by design and continuous manufacturing.面向商业化的制造科学，包括工艺设计、放大、过程分析技术、质量源于设计与连续制造。
• Solid-state and formulation characterisation, excipient compatibility, stability and dissolution behaviour.固体状态与处方表征、辅料相容性、稳定性与溶出行为。
• Biopharmaceutical and analytical evaluation, including bioequivalence and in vitro to in vivo correlation.生物药剂学与分析评价，包括生物等效性与体内外相关性。
• Article types are research articles, expert reviews and mini-reviews, also gathered into themed collections, and uninvited reviews are explicitly welcomed.接受体裁为研究论文、专家综述与小型综述，并结集为主题专辑，且明确欢迎未经邀约的综述。

History

• Volume 1 appeared in 2000, when the association launched the title as a purely electronic journal, and it opened with a From the Editor piece by Wolfgang A. DeLuca.第 1 卷于 2000 年出版，协会当时以纯电子期刊的形式创办本刊，首卷以（Wolfgang A. DeLuca）撰写的编者前言开篇。
• The founders chose an online-only model so that the journal could use emerging electronic tools for faster and more varied delivery of results.创办者选择纯在线模式，是为了借助新兴电子手段更快捷、更多样地传播研究成果。
• The association remains co-publisher and copyright holder, while Springer Nature produces the journal and hosts it on SpringerLink.协会仍是共同出版方与版权持有者，（Springer Nature）负责出版制作并在（SpringerLink）平台托管。
• Articles now appear continuously with article numbers, so a paper can be cited on the day it is published, while numbered issues still group the content.文章现以连续出版方式配以文章编号发布，发表当日即可被引用，编号期次仍用于归集成套内容。
• The 2025 Journal Impact Factor is 5.1, after 4.0 in 2024, 4.026 in 2022 and 3.246 in 2021, and the title ranks 65 of 356 in pharmacology and pharmacy at Q1.2025 年期刊影响因子为 5.1，2024 年为 4.0，2022 年为 4.026，2021 年为 3.246，在药理学与药学类别位列 Q1，排名 65/356。
• It is indexed in MEDLINE, SCIE, Scopus, EMBASE, Chemical Abstracts Service, Dimensions and ProQuest.本刊被（MEDLINE）、（SCIE）、（Scopus）、（EMBASE）、（Chemical Abstracts Service）、（Dimensions）与（ProQuest）收录。

Editors

• Robert O. Williams III of the University of Texas at Austin is Editor-in-Chief, with research on drug delivery, nanoparticle formulations and pulmonary administration.得克萨斯大学奥斯汀分校的（Robert O. Williams III）任主编，研究药物递送、纳米粒处方与肺部给药。
• A group of international editors and an Editorial Advisory Board support the Editor-in-Chief, and the roster is published on the journal site.一个国际编辑团队与编辑顾问委员会协助主编工作，名单在期刊网站公布。
• Springer reports an average first decision time of 30 days and presents the fast turnaround as one of the journal's attractions for authors.（Springer）公布的平均初审决定时间为 30 天，并将这一速度作为本刊吸引作者的卖点之一。
• Declined authors may opt into portable peer review, which shares referee comments and reviewer names, with consent, across AAPS Open, The AAPS Journal, AAPS PharmSciTech and Pharmaceutical Research.被拒稿的作者可选择“可携带同行评审”，在各方同意的前提下，让评审意见与审稿人姓名在（AAPS Open）、（The AAPS Journal）、（AAPS PharmSciTech）与（Pharmaceutical Research）之间共享。
• The journal is hybrid open access, charges no colour fee, accepts video and other supplemental files, and receives manuscripts through Editorial Manager.本刊为混合开放获取，不收彩图费，接受视频等补充材料，并通过（Editorial Manager）接收稿件。